SM88 Shows Encouraging Survival Trends in Advanced Pancreatic Cancer

SM-88 Shows Encouraging Survival Trends in Advanced Pancreatic Cancer

The oral modified dysfunctional tyrosine SM-88 demonstrated a median overall survival of 6.4 months in patients with advanced pancreatic cancer.

Original Article: SM-88 Shows Encouraging Survival Trends in Advanced Pancreatic Cancer

More From BioPortfolio on "SM-88 Shows Encouraging Survival Trends in Advanced Pancreatic Cancer"